Table 3 Incidence of most frequent AEs (≥2% for either group) by preferred term (safety population)
| Â | Lumiracoxib 400 mg od (n= 154) n(%) | Rofecoxib 25 mg od (n= 155) n(%) |
|---|---|---|
Dyspepsia | 41 (26.6) | 33 (21.3) |
Abdominal pain NOS | 15 (9.7) | 10 (6.5) |
Diarrhoea NOS | 15 (9.7) | 7 (4.5) |
Nausea | 8 (5.2) | 8 (5.2) |
Abdominal pain upper | 4 (2.6) | 7 (4.5) |
Constipation | 4 (2.6) | 1 (0.6) |
Oedema lower limb | 6 (3.9) | 7 (4.5) |
Fatigue | 5 (3.2) | 4 (2.6) |
Nasopharyngitis | 9 (5.8) | 9 (5.8) |
Influenza | 6 (3.9) | 6 (3.9) |